Oncozene™ Microspheres

Indications, Safety, and Warnings

Prescriptive Information

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Directions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.


Oncozene Microspheres Microspheres are indicated for the embolization of arteriovenous malformations and hypervascular tumors including hepatoma.


Embolization procedures shall not be performed if:

• Patient is unable to tolerate vascular occlusion procedures.
• Vascular anatomy precludes correct catheter placement or embolic injection.
• Presence or likely onset of vasospasm.
• Presence of a blood coagulation disorder that would prohibit arterial punctures.
• Presence of severe atheromatous disease that would preclude correct catheter placement.
• Presence of patent extra-to-intra-cranial anastomoses or shunts from the arterial to the venous circulation.
• Presence of collateral vessel pathways which could potentially endanger non-targeted tissue during an embolization procedure.
• Presence of any vasculature where ONCOZENE Microspheres could pass directly into the central nervous system, central circulatory system, or other non-target territories.
• Patient has high-flow arteriovenous shunt with diameter greater than the selected ONCOZENE Microspheres.
• Patient is pregnant.
• Patient has known allergies to barium sulfate, 3-aminopropyltrialkoxysilane, polyphosphazene or IV radiopaque contrast agent.


Vascular embolization is a high-risk procedure. The procedure should be performed by specialized physicians trained in vascular embolization procedures. Complications can occur at any time during or after the procedure, and may include, but not be limited to:

• Undesirable reflux or passage of ONCOZENE Microspheres into normal arteries adjacent to the targeted lesion or through the lesion into other arteries or arterial beds.
• Embolization of the wrong artery or migration of the microspheres to other parts of the body, which may necessitate further treatment.
• Hematoma, or bruising, at the incision site for arterial access.
• Arterial aneurysm at the incision site for arterial access.
• Deep vein thrombosis, or clotting of a deep vein in patient’s leg(s).
• Thrombosis of the artery at the incision site for arterial access.
• Pulmonary embolization.
• Ischemia at an undesirable location.
• Capillary bed saturation and tissue damage.
• Ischemic stroke or ischemic infarction.
• Vessel or lesion rupture and hemorrhage.
• Neurological deficits including cranial nerve palsies.
• Vasospasm.
• Recanalization.
• Foreign body reactions necessitating medical intervention.
• Infection necessitating medical intervention.
• Clot formation at the tip of the catheter and subsequent dislodgement.
• Allergic reaction.
• Risks of radiation from angiography and fluoroscopy used to visualize the blood vessels during embolization, which may include a radiation burn and risks to future fertility.
• Death.

Do not use ONCOZENE Microspheres in conjunction with embolization devices based on organic solvents such as ethyl alcohol or dimethyl sulfoxide (DMSO) at the same embolization site.

Do not use ionic contrast agent with this product. Ionic contrast agents could alter the microsphere characteristics resulting in microsphere deformation and procedure failure.


To maintain safety, the following precautions shall be considered:

• The physician should carefully select the size and quantity of ONCOZENE according to the lesion to be treated based on the physician’s education and training and currently available scientific evidence.
• Physicians must decide the most appropriate time to stop the infusion of ONCOZENE Microspheres. Typically, the artery will accept fewer ONCOZENE Microspheres as the treatment progresses. Proximal slowing or termination of flow may indicate that the vessel or the target area is occluded by ONCOZENE Microspheres. Careful fluoroscopic monitoring is required.
• Microparticle embolization must be performed slowly. The injection speed and manner must be controlled Excessive injection rate may result in retrograde flow in the vessel leading to embolization of other nontarget, healthy tissue or organs.
• Safety and effectiveness of ONCOZENE Microspheres in the treatment of uterine fibroids has not been established.
• Safety and effectiveness of ONCOZENE Microspheres for renal embolization uses has not been established.
• If arteriovenous anastomoses, branch vessels which lead away from the targeted embolization area, or emergent vessels not evident prior to embolization are present, it can lead to non-targeted embolization and cause severe complications for the patient.
• Particles smaller than 100 μm can migrate to distal anastomotic feeders and embolize circulation to distal tissue. For this reason, smaller particles have a greater likelihood of causing unwanted ischemic injury. This should be considered prior to starting the embolization procedure. Possible consequences include, but are not limited to, paralysis, necrosis, swelling, abscess formation and more severe post-embolization syndrome.
• Ischemia of tissue adjacent to the targeted area may result from post-embolization swelling. Therefore, special care should be taken to avoid such ischemia of non-tolerant, non-targeted tissue such as the nervous system.
• Consider upsizing ONCOZENE Microspheres if angiographic appearance of embolization does not quickly appear during injection of the microspheres.
• If there are any symptoms of unwanted embolization during injection, consider stopping the procedure to evaluate the possibility of shunting. Such symptoms may include changes in patient vital signs, such as hypoxia or central nervous system changes.